Article -> Article Details
Title | Alagille Syndrome Market Showcases Promising Growth by 2023 |
---|---|
Category | Fitness Health --> Addictions |
Meta Keywords | Alagille Syndrome Market |
Owner | vinit |
Description | |
Market Analysis Global Alagille
Syndrome Market is likely to grow at a healthy CAGR between 2018-
2023, states the Market Research Future (MRFR) report. Alagille syndrome, simply
put, is a rare genetic disorder that impacts various organ systems of the body,
especially kidneys, eyes, skeleton, heart, and liver. It is related to biliary
atresia, hepatomegaly, and liver diseases, and liver transplantation may be
needed in severe cases. Neurologic problems, distinctive facial features, heart
problems, nutrition problems, liver problems, and others are some of its
symptoms. Some of the most effective treatments for alagille syndrome include
heart surgery, kidney surgery, liver transplantation, vitamin supplements,
biliary diversion procedures, medication, and others. Various factors are adding to the global alagille syndrome
market growth. These factors, according to the new MRFR report, include huge
financial support for researchers to develop a novel intervention, increasing
cases of paragangliomas, constant advancements in the treatment, rising
prevalence of cancer, and rise in special designation from regulatory
authorities. Market Segmentation The MRFR report offers an inclusive segmental analysis of
the global alagille syndrome market based on end user, diagnosis, treatment,
and symptom. By Symptom, the alagille syndrome market is segmented into
neurologic problems, distinctive facial features, heart problems, nutrition
problems, liver problems, and others. By Treatment, the alagille syndrome market is segmented into
heart surgery, kidney surgery, liver transplantation, vitamin supplements,
biliary diversion procedures, medication, and others. The medication segment is
again segmented into anti-histamine, naltrexone, rifampin, cholestyramine,
Ursodeoxycholic. The anti-histamine segment is further segmented into
hydroxyzine & others. By Diagnosis, the alagille syndrome market is segmented into
prenatal DNA testing, generic testing, liver biopsy, slit-lamp exam, cardiology
exam, X-ray imaging, urinalysis, blood test, and others. By End User, the alagille syndrome market is segmented into
diagnostic centers, hospitals and clinics, and others. Regional Analysis Based on the region, the global alagille syndrome market
covers the growth opportunities and recent trends across the Asia Pacific
(APAC), the Americas, Europe, & the Middle East & Africa (MEA). Among
these, the Americas will spearhead the market over the forecast period. Factors
adding market growth include growing healthcare expenditure, increasing cases
of rare genetic disease, and well-developed healthcare sector. Besides,
well-developed technology and increasing awareness among people are also adding
market growth. The global alagille syndrome market is predicted to hold the
second-largest share over the forecast period for increasing healthcare
expenditure, accessibility of funds for R&D, rising cases of genetic
disease, and increasing prevalence of different liver diseases. The global alagille syndrome market in the Asia Pacific
region is likely to develop at a quick rate during the forecast period. The
increasing funding in the healthcare sector by the government, rising prevalence
of rare diseases, constantly developing economies, and a huge patient
population is adding market growth. The global alagille syndrome market in the MEA will have the
smallest share over the forecast period. A favorable share will be held by the eastern
region for the increasing initiatives by the government, especially for the
healthcare industry and the presence of a well-developed healthcare sector. Key Players Leading players profiled in the alagille syndrome market
report include Merck & Co., Inc, GlaxoSmithKline Plc, Bristol-Myers Squibb
Company, Shire, Pfizer, Inc., Novartis AG, AstraZeneca Plc, Albireo Pharma,
Inc., Allergen Plc, Lannett, Teva Pharmaceutical Industries Ltd., and Sanofi
AG. Industry players have encompassed strategies such as acquisitions and
mergers, new product launch, joint ventures, collaborations, and others to
create a niche in the market. |